3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Skin Neoplasms
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hot Flashes
2
Vulvodynia
1
Thromboembolism
1
Severe Acute Respiratory Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Hemorrhage
1
Pleural Effusion, Malignant
1
Platinum Resistant Ovarian Cancer
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Neutropenia
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
pegfilgrastim
9
Filgrastim
6
eflapegrastim
3
Docetaxel
3
Cyclophosphamide
3
posaconazole
1
plerixafor
1
isavuconazole
1
ceftobiprole medocaril
1
angiotensin I (1-7)
1
Vancomycin
1
Sodium Chloride
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Levofloxacin
1
Itraconazole
1
Granulocyte Colony-Stimulating Factor
1
Fluconazole
1
EC regimen
1
Daptomycin
1
Cefepime
1
Caspofungin
1
Bevacizumab
1
Algorithms
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts